Pharmaceutical omega-3 products are important but will grow more slowly than some expect because of the long timeframe for drug approval, says the chief of the Global Organisation for EPA and DHA Omega-3s (GOED).
Just got off the phone to Ola Snove, the new(ish) CEO of Aker part-owned Norwegian omega-3 specialist Epax. Wanted to know his view on high-end omega-3 prospects that have attracted BASF and DSM to the sector. His word: “Stellar”.
Global probiotics leader Chr Hansen is throwing €20m at the expansion of its Danish freeze-drying capacity with increasing global pharma and food supplement demand the key driver.
The dietary supplements industry should be encouraged and not threatened by increased scrutiny of its products by the mainstream medical community, because it means they are taking the products – and the questions from their patients – seriously.
The next 5-10 years will present a significant challenge for global business, with a new event promising to help business leaders navigate the ‘biggest period of global change since the industrial revolution’.
BASF says revised offer for omega-3 API maker Pronova Biopharma is fair value given recent Greek Government decision to stop reimbursing two key drugs.
The economic crisis has hit the EU hard, and coupled with a severe health and nutrition claim clamp down, the past years have been challenging for the European nutra industry.
